Therefore, we propose the use of erastin, a SLC7A11 inhibitor, to block the RFNG‐p53‐SLC7A11 axis and enhance the sensitivity of CRC cells to oxaliplatin by promoting ferroptosis. Here, SLC7A11 is linked to colorectal carcinoma.